← All trials
NCT04386057
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Mar 18, 2022
- Completion date
- Sep 19, 2022
- First posted
- May 13, 2020
- Last posted
- May 13, 2020
- Enrollment
- 52
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversitySponsor investigator
- Harvard UniversityOverall official - principal investigator
- Eli LillyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.